-transparent.png){kind=logo}
Fourteen healthy males received two 75-mg doses of amrinone as a single capsule and as an intravenous solution in a single-dose crossover study. The mean (+/-SD) bioavailability, based on the area under the plasma concentration versus time curves, was 0.93 +/- 0.12. The plasma data for these subjects during the intravenous phase was described by an open two-compartment body model with a mean (+/-SD) apparent first-order terminal elimination rate constant, beta, of 0.19 +/- 0.06 hr-1, which corresponds to a half-life of 3.6 hr.
Related Publications
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
January 1988,
European journal of clinical pharmacology,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
January 1979,
Journal of pharmaceutical sciences,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
June 1982,
Journal of pharmacokinetics and biopharmaceutics,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
June 2018,
Journal of analytical toxicology,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
December 1994,
Arzneimittel-Forschung,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
December 1980,
Journal of pharmaceutical sciences,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
December 1983,
Antimicrobial agents and chemotherapy,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
July 2021,
Xenobiotica; the fate of foreign compounds in biological systems,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
May 1982,
Die Pharmazie,
G B Park, and
R P Kershner, and
J Angellotti, and
R L Williams, and
L Z Benet, and
J Edelson
October 1982,
Journal of clinical pharmacology,
